Testing how other drugs affect a new leukemia tablet
Treatments studied
This study looks at how two common medicines, itraconazole and rifampin, change the levels of a new drug called Rocbrutinib in healthy volunteers. The results will help doctors understand how to use Rocbrutinib safely in future patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 45 years old
- Be in good general health with no major medical problems
- Not smoke more than 5 cigarettes a day or use tobacco
- Not drink alcohol excessively or use illegal drugs
- Not take any other medicines or supplements for 2 weeks before the study
- Agree to use birth control or avoid pregnancy for 90 days after the last dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted therapy called Rocbrutinib against other BTK inhibitors for people with mantle cell lymphoma that has come back or not responded to prior treatment. It aims to see which works better and how safe they are.
This study tests a new oral medication called Rocbrutinib for people with relapsing-remitting multiple sclerosis (RRMS). The drug targets a protein that may help reduce the immune system's attack on the brain and spinal cord. The trial will check if the medication can reduce new brain lesions and slow down disability progression.
This trial tests a combination of two new drugs (rocbrutinib and lacutoclax) to treat B-cell lymphomas and leukemias. The goal is to see if this combination works better than standard treatments, especially for patients whose cancer has come back or stopped responding to previous therapy.
This study tests an experimental pill (TQB3911) for people with chronic myeloid leukemia (CML) who have not responded well to or could not tolerate standard treatments. The goal is to find out if the drug is safe and what side effects it may cause.
This study checks how the investigational medicine rilzabrutinib affects proteins in your body that help clear certain drugs. It helps make sure other medications you take are safe and work properly.
This study tests whether combining a new drug called rocbrutinib with standard chemotherapy (R-GemOx) works better for patients whose diffuse large B-cell lymphoma (a type of blood cancer) has stopped responding to previous treatments. Researchers hope this combination may help patients who have limited options.
Hear when a new Clinical Pharmacology trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.